In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Xtandi data bolster case for pre-chemo use

This article was originally published in Scrip

Executive Summary

Astellas and Medivation reported a 10-month progression-free survival benefit for Xtandi (enzalutamide) versus Casodex (bicalutamide) in a Phase II clinical trial designed to satisfy requests for a head-to-head comparison of the androgen receptor inhibitors in metastatic castrate-resistant prostate cancer (mCRPC).

You may also be interested in...



Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation

As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations

After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.

Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar

Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC027592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel